Two competing buyout bids and a $501M cash pile make this a deal story, not a product story — outcome hinges on whether either acquirer prevails

InMode is a profitable, commercial-stage medical aesthetics device company whose lead product, Morpheus8, is already approved and currently under acquisition review by two competing bidders.

InMode, a profitable medical aesthetics device company, sits on $501M in cash while two competing acquisition bids (CEO group at $16.20/share and Steel Partners) are under Special Committee review. The thesis resolves on whether a deal closes at an acceptable premium, as a second failed transaction process would likely reprice the stock toward fundamentals. Core risks are margin erosion (operating margin fell from 20% to 12% year-over-year) and a patent infringement suit targeting the Morpheus8 product line.